| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
This compound is a taxane diterpene. It does not have a well-defined specific protein target like other taxanes. Instead, it is a natural product building block, known to have concentration-dependent nitric oxide (NO) inhibitory activity in cell-based assays.
|
|---|---|
| ln Vitro |
1-Dehydroxybaccatin IV shows concentration-dependent nitric oxide (NO) inhibition activity, with an IC50 of 32.2 microM. This indicates potential anti-inflammatory activity by reducing the production of the inflammatory mediator NO. Detailed antiproliferative activity is not extensively documented.
|
| ln Vivo |
Dedicated in vivo efficacy studies for 1-Dehydroxybaccatin IV are not extensively documented. As a taxane diterpene, it is structurally related to the anticancer drug paclitaxel, but its bioactivity profile differs significantly and is primarily studied in vitro.
|
| Enzyme Assay |
The nitric oxide (NO) inhibitory activity is assessed in cell-based assays. Macrophage cell lines (e.g., RAW 264.7) are stimulated with lipopolysaccharide (LPS) in the presence of varying concentrations of 1-Dehydroxybaccatin IV. Nitrite accumulation in the culture medium is measured using the Griess reagent system.
|
| Cell Assay |
RAW 264.7 macrophages are cultured in DMEM with 10% FBS. Cells are treated with 1-Dehydroxybaccatin IV and then stimulated with LPS for 24 hours. Cell culture supernatants are collected, and nitrite levels are quantified by Griess assay. Cell viability is assessed to rule out cytotoxicity.
|
| Animal Protocol |
Dedicated in vivo protocols for 1-Dehydroxybaccatin IV are not well-documented. A standard protocol would involve intraperitoneal injection in murine models of inflammation (e.g., carrageenan-induced paw edema). Serum NO levels would be measured.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for 1-Dehydroxybaccatin IV are not extensively documented. As a complex diterpene with multiple acetate groups, its solubility and bioavailability are likely limited. It is primarily isolated from natural sources for research purposes.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for 1-Dehydroxybaccatin IV is not available. As a natural product, it is not intended for clinical use, and comprehensive animal toxicity studies have not been performed. Standard laboratory handling precautions are sufficient.
|
| References | |
| Additional Infomation |
It has been reported that yew and Chinese yew contain 1-dehydroxybaccatin IV, and there is relevant data.
1-Dehydroxybaccatin IV is a biosynthetic precursor to more complex taxanes, including paclitaxel. It serves as a research tool and analytical reference standard for studying taxane chemistry and natural product biosynthesis. It is strictly for research use and not a clinical candidate. |
| Molecular Formula |
C32H44O13
|
|---|---|
| Molecular Weight |
636.683971405029
|
| Exact Mass |
636.278
|
| CAS # |
57672-78-3
|
| PubChem CID |
21679297
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O1C[C@@]2([C@H]1C[C@@H]([C@@]1(C)[C@H]([C@@H](C3=C(C)[C@H](C[C@H](C3(C)C)[C@H]([C@@H]12)OC(C)=O)OC(C)=O)OC(C)=O)OC(C)=O)OC(C)=O)OC(C)=O
|
| InChi Key |
GHSKUVKACGPNGN-CZYGJQDOSA-N
|
| InChi Code |
InChI=1S/C32H44O13/c1-14-22(40-15(2)33)11-21-26(42-17(4)35)28-31(10,23(41-16(3)34)12-24-32(28,13-39-24)45-20(7)38)29(44-19(6)37)27(43-18(5)36)25(14)30(21,8)9/h21-24,26-29H,11-13H2,1-10H3/t21-,22-,23-,24+,26+,27+,28-,29-,31+,32-/m0/s1
|
| Chemical Name |
[(1R,2R,3R,4S,7R,9S,10S,11R,12R,15S)-2,4,9,11,12-pentaacetyloxy-10,14,17,17-tetramethyl-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-15-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5706 mL | 7.8532 mL | 15.7065 mL | |
| 5 mM | 0.3141 mL | 1.5706 mL | 3.1413 mL | |
| 10 mM | 0.1571 mL | 0.7853 mL | 1.5706 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
